Business Wire

IL-SHIPPEO

Share
Shippeo Named a Leader in the 2024 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms, Announces Record Growth in North America and APAC

Shippeo has been named a Leader in the 2024 Gartner® Magic Quadrant for Real-Time Transportation Visibility Platforms. The global multimodal shipment visibility platform was also recently named a Customers’ Choice by Gartner® in the October 2023 Gartner Peer Insights™ “Voice of the Customer”: Real-Time Transportation Visibility Platforms report, scoring the highest customer recommendation willingness rate of all providers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402784237/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Shippeo)

“We are delighted to be recognized as a Leader in this latest Gartner research,” says Shippeo CEO & co-founder, Pierre Khoury. “We are also deeply thankful for the support of our wonderful customers and ecosystem partners, and incredibly proud of our talented teams. As the real-time transportation visibility (RTTV) market continues to mature in North America, Europe, and increasingly across APAC, companies are realizing the significant value visibility brings. From increasing customer NPS with more premium delivery experiences, to reducing operating costs, optimizing processes and cash flow, and monitoring and reducing carbon emissions, our platform is being recognized as an important enabler of next-generation supply chains.”

Strong growth and market momentum in North America, Asia Pacific and Europe

Over the past two years, the company’s customer base tripled. In 2023, the North American revenue grew 153% year over year, with 25% of all new revenue generated having come from companies in this region switching to Shippeo from another provider. Notable new North American customers include Amazon, Barilla, and Palermo Villa, Inc. (dba Palermo’s Pizza). The company also significantly grew its customer base in Asia Pacific, welcoming some of the region’s most recognizable brands, including Yamaha Motor. Notable customers joining in other parts of the world include Arlanxeo, Birra Peroni, DP World, Evonik, Fujifilm and Hartmann Group.

“Our approach to visibility with a greater focus on data quality and customer support has resonated extremely well with the RTTV market in North America,” says Lucien Besse, COO & co-founder at Shippeo. “Since 2020, our partnership with e2open has blossomed into a powerhouse collaboration. Through close cooperation and a shared commitment to excellence, we've achieved remarkable success together, in North America and abroad. This enduring partnership underscores our collective ability to innovate and thrive in today's dynamic landscape.”

Global multimodal visibility network

With established regional head offices in Chicago for the Americas, Singapore for APAC, and Paris for Europe, Shippeo’s network now tracks more than 50 million shipments a year across all modes, in more than 130 countries on six continents, with a 258,000-strong carrier network. Their ocean visibility network covers 99% of the world’s containerships thanks to integrations with major shipping lines. The company’s partner network has also enjoyed continued momentum, now comprising over 1000 system integrations with TMS, WMS, ERPs and telematics devices, representing a 30% increase since the start of 2022. Key strategic partners include e2open, SAP, Infor, Tesisquare, Alpega, Oracle, Siemens, Google, Snowflake, Microsoft, and BlueYonder.

The most recommended provider for three years running

Shippeo has had the highest recommendation rate of all providers on Gartner Peer Insights for over three years. In October 2023, the company was positioned in the Customers’ Choice Quadrant, having scored a 96% recommendation rate, the highest of all providers (based on 116 reviews as of August 2023).

www.shippeo.com/press-releases/shippeo-named-a-leader-in-the-2024-gartner-magic-quadrant-for-real-time-transportation-visibility-platforms

Disclaimer:
GARTNER is a registered trademark and service mark and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
G
artner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2024” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 26 March 2024.

Gartner, “Voice of the Customer for Real-Time Transportation Visibility Platforms”, by Peer Contributors, 31 October 2023.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular Purpose.

Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240402784237/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release

Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e

Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release

Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa

Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release

News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye